Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 7.8.2023 | EN | Official Journal of the European Union | C 278/3 |

---

Judgment of the Court (Third Chamber) of 22 June 2023 — Federal Republic of Germany (C-6/21 P), Republic of Estonia (C-16/21 P) v Pharma Mar SA, European Commission

(Joined Cases C-6/21 P and C-16/21 P) [(1)](#ntr1-C_2023278EN.01000301-E0001)

(Appeal - Public health - Medicinal products for human use - Regulation (EC) No 726/2004 - Refusal of a marketing authorisation for the medicinal product for human use - Aplidin — plitidepsin - European Medicines Agency (EMA) - Impartiality of experts from a scientific advisory group (SAG) - Policy of the European Medicines Agency on the handling of competing interests of scientific committees’ members and experts - Concept of ‘pharmaceutical company’ - Scope of the exclusion for ‘research organisations’ - Concept of ‘rival products’)

(2023/C 278/03)

Language of the case: English

Parties

Appellants: Federal Republic of Germany (C-6/21 P) (represented initially by J. Möller and S. Heimerl, and subsequently J. Möller and P.-L. Krüger, acting as Agents), Republic of Estonia (C-16/21 P) (represented by: N. Grünberg, acting as Agent)

Other parties to the proceedings: Pharma Mar SA (represented by: M. Merola and V. Salvatore, avvocati), European Commission (represented by: L. Haasbeek and A. Sipos, acting as Agents)

Interveners in support of the applicant (C-6/21 P): Kingdom of the Netherlands (represented by: M.K. Bulterman, J. Langer and C.S. Schillemans, acting as Agents), European Medicines Agency (EMA) (represented by: S. Drosos, H. Kerr and S. Marino, acting as Agents)

Interveners in support of the applicant (C-16/21 P): Federal Republic of Germany (represented initially by J. Möller and S. Heimerl, and subsequently J. Möller and D. Klebs, and, lastly, J. Möller and P.-L. Krüger, acting as Agents), Kingdom of the Netherlands (represented by: M.K. Bulterman, J. Langer and C.S. Schillemans, acting as Agents), European Medicines Agency (EMA) (represented by: S. Drosos, H. Kerr and S. Marino, acting as Agents)

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Sets aside the judgment of the General Court of the European Union of 28 October 2020, Pharma Mar v Commission (T 594/18, not published, EU:T:2020:512); |

|  |  |
| --- | --- |
| 2. | Refers Case T 594/18 back to the General Court of the European Union; |

|  |  |
| --- | --- |
| 3. | Reserves the costs. |

---

---

[Top](#document1)